Please assess the completion status of the following clinical trial:

Trial Title: Ph 2/3 Study in Subjects With MPM to Assess ADI-PEG 20 With Pemetrexed and Cisplatin

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically proven unresectable MPM of biphasic or sarcomatoid histology~* Naïve to chemotherapy or immunotherapy~* ECOG PS 0-1~* Expected survival of at least 3 months~* Age 18 years or over (there is no upper age limit)~* Measurable disease by modified RECIST criteria for MPM for local pleural disease and RECIST 1.1 criteria for metastatic lesions~* Written (signed and dated) informed consent and must be capable of co-operating with treatment and follow up~* Adequate hematologic, hepatic, and renal function~Exclusion Criteria:~* Radiotherapy (except for palliative reasons) in the previous two weeks before study treatment~* History of unstable cardiac disease~* Ongoing toxic manifestations of previous treatments~* Symptomatic brain or spinal cord metastases (patients must be stable for \> 1 month post radiotherapy or surgery)~* Major thoracic or abdominal surgery from which the patient has not yet recovered.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Drug: ADI-PEG 20 plus Pem Platinum (Type: EXPERIMENTAL): Dose: 36 mg/m2 given weekly Route of Administration: Intramuscular (IM) Duration : Course of Study~In Combination With:~Pemetrexed Dose: 500 mg/m2 every 3 weeks Route of Administration: Intravenous Cisplatin Dose: 75 mg/m2 every 3 weeks Route of Administration: Intravenous Carboplatin Dose: AUC 5 mg/mL/min every 3 weeks Route of Administration: Intravenous~ADI-PEG 20 plus Pem Platinum: Investigational Drug in combination approved standard of care treatment for this indication
- Drug: Placebo plus Pem Platinum (Type: PLACEBO_COMPARATOR): Dose: 36 mg/m2 given weekly Route of Administration: Intramuscular (IM) Duration : Course of Study~In Combination With:~Pemetrexed Dose: 500 mg/m2 every 3 weeks Route of Administration: Intravenous Cisplatin Dose: 75 mg/m2 every 3 weeks Carboplatin Dose: AUC 5 mg/mL/min every 3 weeks Route of Administration: Intravenous~Placebo plus Pem Platinum: Placebo in combination approved standard of care treatment for this indication

Based on this trial design, predict the completion outcome and termination type (if applicable).